Skye Bioscience, Inc.
As of Oct 22, 2026, Skye Bioscience is in Stage 4, the downtrend phase, now in week 16 (since Jul 7, 2026). It closed at $1.62, 87.4% below its 52-week high and below its 200-day average, which is falling.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SKYE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SKYE among Biotechnology491st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …491 | SKYE | Stage 4 · wk 16 | 9 | −10.0% |
Skye Bioscience: quick answers
What stage is Skye Bioscience in?
As of Oct 22, 2026, Skye Bioscience (SKYE) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 7, 2026 and is in week 16. What the four stages mean
Is Skye Bioscience in an uptrend?
No. Skye Bioscience is in a Stage 4 downtrend. It trades 68.0% below its 200-day average, which is falling.
How far is Skye Bioscience from its 52-week high?
Skye Bioscience closed at $1.62 on Oct 22, 2026, 87.4% below its 52-week high of $12.88. Its 52-week low is $1.53.
How has Skye Bioscience performed over the past year?
As of Oct 22, 2026, Skye Bioscience is down 86.0% over the past year and down 76.9% so far in 2026.
Which sector and industry is Skye Bioscience in?
Skye Bioscience is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.